Vergelijking
Glepaglutide vs. Gonadorelin
Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.
Identiteit
Categorie
Onderzoek (overig)
Onderzoek (overig)
CAS-nr.
geen gegevens
33515-09-2
Molecuulmassa
geen gegevens
1182.29 g/mol
Halfwaardetijd
geen gegevens
0.1 h
Sequentie
geen gegevens
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2Werkingsmechanisme
Glepaglutide
As a GLP-2 receptor agonist, glepaglutide has a trophic effect on the intestinal mucosa, enlarging the absorptive surface and thereby improving intestinal uptake of nutrients and fluid.
Gonadorelin
Gonadorelin acts as an agonist at the GnRH receptor on the gonadotroph cells of the pituitary and triggers release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The temporal pattern of receptor exposure is decisive: pulsatile administration mimics the natural hypothalamic secretory rhythm and sustains LH/FSH release, whereas continuous exposure leads to receptor internalisation and desensitisation with subsequent paradoxical suppression of gonadotropins. The latter principle is exploited therapeutically by longer-acting GnRH agonists.
Bewijsbasis
Hoogste bewijs
Humane RCT
Humane studie
Studies
1
4
waarvan bij mensen
1
4
Geregistreerde effecten
2
4
Openstaande tegenstrijdigheden
0
1
Gedocumenteerde bijwerkingen
1
2
Juridische status
Volledige vermeldingen
Frequently asked questions
- What is the difference between Glepaglutide and Gonadorelin?
- Glepaglutide is classified as "Onderzoek (overig)", while Gonadorelin is classified as "Onderzoek (overig)". Glepaglutide: Glepaglutide is a long-acting GLP-2 analogue (Zealand Pharma) intended to reduce the need for parenteral support in short bowel syndrome. Gonadorelin: Gonadorelin is the synthetic decapeptide with an amino-acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH/LHRH). Historically approved in several countries for diagnostic testing of pituitary function and for fertility indications (pump systems). A defining feature is the opposite effect of pulsatile versus continuous administration: pulsatile stimulates, continuous leads to receptor desensitisation. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Glepaglutide or Gonadorelin?
- The highest available evidence level is "Humane RCT" for Glepaglutide and "Humane studie" for Gonadorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Glepaglutide and Gonadorelin in Germany and the United States?
- Duitsland: Glepaglutide — Niet goedgekeurd, Gonadorelin — Op recept. Verenigde Staten: Glepaglutide — Niet goedgekeurd, Gonadorelin — Op recept. These are factual summaries with source and review date on the individual pages.